Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History BTAI

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics BTAI

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield
Consecutive Years
Forward Annual Dividend – USD
Consistent Years
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date

BioXcel Therapeutics Inc

BTAI
Current price
1.94 USD 0 USD (0.00%)
Last closed 1.90 USD
ISIN US09075P2048
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 11 809 298 USD
Yield for 12 month -90.22 %
1Y
3Y
5Y
10Y
15Y
BTAI
21.11.2021 - 28.11.2021

BioXcel Therapeutics, Inc., together with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology in the United States. The company IGALMI, a sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. It also develops its neuroscience candidate, BXCL501, which is an investigational, proprietary, orally dissolving film formulation of dexmedetomidine in Phase 3 trial for the treatment of agitation associated with bipolar disorders, schizophrenia, and Alzheimer's disease, as well as opioid use disorder, alcohol use disorder with comorbid post-traumatic stress disorder, and acute stress disorder; and its immune-oncology candidate, BXCL701, which is an investigational oral innate immune activator that has completed Phase 1b/2a trial for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors. In addition, the company engages in the development of BXCL502 for the treatment of stress-related neuropsychiatric symptoms in dementia and other stress-related disorders; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, which has the potential to address apathy and aggression in dementia. The company has collaborations with Columbia University, Yale University Medical School, and University of North Carolina for the development of BXCL501. BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut. Address: 555 Long Wharf Drive, New Haven, CT, United States, 06511

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

23.25 USD

P/E Ratio

Dividend Yield

Financials BTAI

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures BTAI

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

+2 266 000 USD

Last Year

+1 380 000 USD

Current Quarter

+168 000 USD

Last Quarter

+366 000 USD

Current Year

+123 000 USD

Last Year

+120 000 USD

Current Quarter

+168 000 USD

Last Quarter

-466 000 USD
EBITDA -50 433 000 USD
Operating Margin TTM -6 011.31 %
Price to Earnings
Return On Assets TTM -52.47 %
PEG Ratio
Return On Equity TTM -1 766.94 %
Wall Street Target Price 23.25 USD
Revenue TTM 1 852 000 USD
Book Value -16.49 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY -71.10 %
Dividend Yield
Gross Profit TTM -225 000 USD
Earnings per share -11.12 USD
Diluted Eps TTM -11.12 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY
Profit Margin

Stock Valuation BTAI

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 47.03
Price Sales TTM 6.38
Enterprise Value EBITDA -0.75
Price Book MRQ 3.97

Technical Indicators BTAI

For 52 Weeks

1.17 USD 19.84 USD
50 Day MA 1.66 USD
Shares Short Prior Month 317 641
200 Day MA 4.62 USD
Short Ratio 0.76
Shares Short 336 411
Short Percent 5.73 %